Amgen buys back rights to three drugs from GSK
December 15, 2015Research and Development, Sales and Marketing Amgen, GSK
Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …
AstraZeneca invests £75m to future-proof production facilities
December 15, 2015Manufacturing and Production AstraZeneca, manufacturing, production
AstraZeneca says it will invest £75m to future-proof a key production facility in Macclesfield, Cheshire. The upgrade to the 48-year-old …
Pharma giants Sanofi and Boehringer negotiate deal to swap assets
December 15, 2015Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt
Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …
GSK in malaria collaboration with Comic Relief
December 15, 2015Manufacturing and Production Comic Relief, GSK, corporate social responsibility, csr, malaria
GSK and UK-based charity Comic Relief have launched a five-year partnership to fight malaria and improve health in five countries …
Bristol-Myers Squibb chooses UCLA as latest research partner
December 14, 2015Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla
Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …
Ablynx sets focus on pharma collaborations
December 14, 2015Manufacturing and Production, Research and Development Ablynx, collaboration, nanobodies, partnership
Drug development companies should prioritise strategic pharma collaborations to keep up with the next wave of immuno-oncology treatments, the chief …
Mirror. Signal. Merger. How to deal with a pharma takeover
December 14, 2015Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers
So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
AstraZeneca in $5bn Acerta buyout talks
December 14, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover
AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
Roche lung cancer drug Alecensa gets rapid US approval
December 14, 2015Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer
The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
Novartis earns provisional NICE yes for Entresto
December 11, 2015Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure
NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
M&A activity drives record year for pharma outsourcing deals
December 11, 2015Sales and Marketing Covance, M&A, MA, labcorp, outsourcing
A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …
Eisai’s Halaven shown to restrict further cancer metastasis
December 11, 2015Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda
New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
Which are pharma’s most innovative companies?
December 11, 2015Medical Communications, Research and Development GSK, Roche, research and development
It has been a record-breaking year for the pharmaceutical industry in terms of deals, but what about the underlying innovation …
AstraZeneca deal to delve into the secretome
December 11, 2015Medical Communications, Research and Development AstraZeneca, MedImmune, biologics, secretome
MedImmune, the biologics research and development arm of pharma giant AstraZeneca, has signed a collaboration with Swedish universities and research …
NICE publishes draft guidance on two prostate cancer treatments
December 11, 2015Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer
NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
Regulators to probe Bayer’s Xarelto trial results
December 10, 2015Medical Communications, Research and Development
Bayer’s blockbuster anticoagulant Xarelto is under scrutiny from regulators in Europe and the US, as they try to determine whether …
Novo Nordisk files for new insulin approval
December 10, 2015Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application
Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
Merck/Pfizer Alliance to collaborate on late-stage cancer trials
December 10, 2015Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer
Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …
‘Female Viagra’ CEO leaves company
December 10, 2015Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma
Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
